Clinical Trial Update: A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome [Phase 1]

View source ↗

Summary

La Jolla Pharmaceutical's Phase 1 study of LJPC-501 in patients with Hepatorenal Syndrome was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatorenal Syndrome

Drugs mentioned

• LJPC-501

Snippet

Sponsor: La Jolla Pharmaceutical Company | Conditions: Hepatorenal Syndrome Type I and Type II | Phase 1 | Status: TERMINATED